# Sources — Gwen Ifill

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Bernstein A (*The Washington Post*). “Gwen Ifill, journalist who became staple of public affairs TV shows, dies at 61,” *Anchorage Daily News*, November 14, 2016. Obituary: supports her birth in Queens on September 29, 1955, as the fifth of six children of a Panamanian immigrant who became an African Methodist Episcopal pastor and a homemaker from Barbados; Simmons College (1977), the Baltimore Evening Sun (1981), *The Washington Post* (1984), *The New York Times*, NBC (1994), *Washington Week* and the *NewsHour* (1999) and co-anchor (2013); the 2004 debate question on AIDS among Black women; *The Breakthrough* (2009); that she died on November 14 at a hospice center in Washington, D.C., and that a family member gave the cause as endometrial cancer; recent leaves of absence for ill health; and a friend’s description of her working through chemotherapy. https://www.adn.com/nation-world/2016/11/14/prominent-pbs-journalist-gwen-ifill-dead-at-61-after-illness/
2. Byers D, Stelter B (CNNMoney). “PBS newscaster Gwen Ifill has died,” KSL.com, November 14, 2016. Supports that she had been battling endometrial cancer while covering the election; the racist note at her Boston Herald internship and her hiring after graduating in 1977; *Washington Week in Review* in 1999 and co-anchor of the *NewsHour* in 2013, with her co-anchor the first women to jointly lead a national nightly news broadcast; and, from a close friend, that she was diagnosed with cancer at the end of 2015 or early in 2016, kept it private, took a leave in April for what were described as ongoing health issues due to complications of treatment, returned in May, took another leave in the week before her death, and was in hospice care in Washington, D.C., when she died. https://www.ksl.com/article/42209265
3. PBS NewsHour. “Remembering Gwen,” November 14, 2016. Supports that she died of complications of cancer at 61, her 17 years on the *NewsHour* and *Washington Week*, two vice-presidential debates, and *The Breakthrough*. https://www.pbs.org/newshour/nation/remembering-gwen
4. Ulaby N. “PBS News Anchor Gwen Ifill Dies At 61,” NPR, *All Things Considered*, November 14, 2016. Supports her birth in New York City in 1955 to immigrant parents, federally subsidized housing in her youth, the debate question on AIDS among Black women, and that she was a private person who had been fighting cancer. https://www.npr.org/2016/11/14/502051018/pbs-news-anchor-gwen-ifill-dies-at-61
5. Ehrbar N. “Gwen Ifill, ‘PBS NewsHour’ anchor, is dead at 61,” CBS News, November 15, 2016. Supports the *NewsHour* statement that she died “following several months of cancer treatment.” https://www.cbsnews.com/news/gwen-ifill-pbs-newshour-anchor-is-dead-at-61/
6. The Associated Press. “PBS’ Gwen Ifill, on leave, expected to return in 2 weeks,” InfoNews, May 16, 2016. Published during her life: supports that she told viewers on April 7 she would be off the air for a few weeks for an undisclosed health issue, that PBS said she was doing well, and that she planned to return around Memorial Day. https://infonews.ca/?p=1827610
7. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473
2. American College of Obstetricians and Gynecologists. Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. *Obstet Gynecol* 2026;148(1):e87-e91 (PMID 41990335): transvaginal ultrasound together with endometrial sampling for most people with postmenopausal bleeding, with ultrasound alone only for carefully selected low-risk patients. https://pubmed.ncbi.nlm.nih.gov/41990335/ ; ACOG Committee Opinion No. 734 (2018), which it updates (PMID 29683909). https://pubmed.ncbi.nlm.nih.gov/29683909/
3. Berek JS, et al. FIGO staging of endometrial cancer: 2023. *Int J Gynaecol Obstet* 2023;162(2):383-394 (PMID 37337978). https://pubmed.ncbi.nlm.nih.gov/37337978/
4. Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). *N Engl J Med* 2023;388:2145-2158 (PMID 36972026). https://pubmed.ncbi.nlm.nih.gov/36972026/ ; Eskander RN, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NRG-GY018). *N Engl J Med* 2023;388:2159-2170 (PMID 36972022). https://pubmed.ncbi.nlm.nih.gov/36972022/
5. JEMPERLI (dostarlimab-gxly) prescribing information, DailyMed: 500 mg every 3 weeks for 6 cycles with carboplatin and paclitaxel, then 1,000 mg every 6 weeks, up to 3 years, for primary advanced or recurrent endometrial cancer; immune-mediated adverse reactions. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5
6. Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol* 2021 (PMID 34724392). https://pubmed.ncbi.nlm.nih.gov/34724392/
7. Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. *Gynecol Oncol* 2026;204:109-117 (PMID 41308226). https://pubmed.ncbi.nlm.nih.gov/41308226/
8. ACOG Practice Bulletin No. 147: Lynch syndrome. *Obstet Gynecol* 2014 (PMID 25437740). https://pubmed.ncbi.nlm.nih.gov/25437740/
9. Clarke MA, Devesa SS, Hammer A, Wentzensen N (National Cancer Institute). Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. *JAMA Oncol* 2022;8(6):895-903 (PMID 35511145): mortality highest among Black women overall, by subtype and by stage; rising non-endometrioid mortality; disparities not fully explained by subtype and stage. https://pubmed.ncbi.nlm.nih.gov/35511145/
10. Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. *JAMA Netw Open* 2020;3(5):e204954 (PMID 32412636): a 90% higher mortality than White women, and knowledge gaps about menopause, misinterpretation of bleeding and first-line responses not aligned with risk as mechanisms of delay. https://pubmed.ncbi.nlm.nih.gov/32412636/
11. ASCO guidelines on antiemetics (2020, PMID 32658626), chemotherapy-induced peripheral neuropathy (2020, PMID 32663120) and hepatitis B screening before cancer therapy (2020, PMID 32716741).
12. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), endometrial cancer monograph (universal mismatch repair tumor testing with MLH1 methylation reflex; germline testing if not explained by methylation; immune-related adverse event laboratory tests including TSH, liver tests, glucose and cortisol at baseline and before each checkpoint inhibitor cycle; CA-125 only if raised at diagnosis; examination every three months and CT every six months for stage III disease; no routine vaginal cytology; lymphedema, lifestyle and other-cancer screening) and hypothyroidism monograph. https://patrickrutledge.github.io/topthirty/
13. U.S. Preventive Services Task Force: A and B recommendations, depression (2023), breast cancer (2024), cervical cancer (2018), colorectal cancer (2021) and osteoporosis (2025); CDC Adult Immunization Schedule; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations

## Editorial resolutions

- **Recent-death rule.** Ifill died in 2016, so the rule applies. The case uses only what was reported publicly during her life (the Associated Press report of her April leave) and in obituaries and official statements at her death (*The Washington Post*, CNN, PBS NewsHour, NPR, CBS News). She kept her illness private; the cause of death was given by her family, and the timing of the diagnosis, the reason for the April leave and her work through chemotherapy come from friends quoted in the obituaries (CLM-0006, graded probable). No sick visit is added. Her death is recorded once (CLM-0007), in plain words. No claim concerns mental health or substance use; the modern mood screens are synthetic and below the threshold for a safety assessment.
- **What is not public.** The stage, histology, molecular result and treatment of her cancer were never made public, beyond friends’ references to chemotherapy. Every clinical detail in the modern episode (the bleeding, the biopsy and its histology, the mismatch repair result, the nodal stage, the surgery, dostarlimab, the hypothyroidism, all values) is synthetic and is not a claim about her real illness.
- **Real people.** No relative is named; the family member who gave the cause of death is referred to only as her family. No decision, statement or health fact is attributed to any relative. Her co-anchor and the president she interviewed appear only in history claims about her career; friends quoted in the obituaries are cited as the obituaries’ sources and have no role in the modern episode. The modern family history is left empty so that no health fact is attributed to a real relative, and the Lynch syndrome work-up never assigns a genetic result to anyone: the tumor’s MLH1 loss is explained by promoter methylation, so germline and cascade testing are not needed.
- **Conflicts.** (1) Wikipedia states that she died of breast and endometrial cancer, citing a Politico report that could not be fetched; the *Washington Post* obituary, CNN, NPR and PBS mention only endometrial cancer or cancer, so breast cancer is not used. (2) Her return from the spring leave is dated to May by a friend quoted by CNN, to around Memorial Day by the network’s plan in May, and by the start of June, when she interviewed President Obama; CLM-0005 says she was back by the start of June. (3) The *New York Times* obituary and the Britannica entry could not be fetched and are not cited.
- **Index age and dates.** The index visit on January 5, 2026 maps to January 5, 2016, when she was 60: shortly before the April leave that was the first public sign of her illness, and within the period a friend later gave for the diagnosis. The synthetic date of birth is September 29, 1965 (shift 10 years). The chronic-care visits on January 20, February 24, April 28 and June 30, 2026, the surgery on February 3, and the preventive visit on August 11, 2026 (age 60, so a periodic adult preventive visit) map to the same days of 2016, before her death. The claim about the diagnosis and treatment is linked to the November 2016 reports, so the intake documents do not show it. There is no past medical or family history from the public record before the index date.
- **Synthetic clinical picture and teaching points.** The presenting problem is postmenopausal bleeding (N95.0), resolved at the consultation when the biopsy gives the diagnosis. The diagnosis is endometrioid, low-grade (grade 2) and mismatch repair deficient, staged FIGO 2023 IIIC2ii at surgery with the molecular class MMRd (POLE wild-type, p53 wild-type), chosen so that the treatment teaches the current standard for mismatch repair deficient advanced disease (dostarlimab with carboplatin and paclitaxel, the RUBY regimen, which covers stage IIIC2 regardless of measurable disease; pembrolizumab with the same chemotherapy is the alternative). The teaching points on equity are explicit in the plan and the teaching objective: Black women in the United States have roughly twice the endometrial cancer mortality of White women, with more non-endometrioid and p53-abnormal tumors, later stage, and delays in evaluating bleeding, and the disparity is not fully explained by subtype and stage (Clarke 2022; Doll 2020). The modern episode models the opposite of delay: any bleeding after menopause is examined and sampled at the first visit, together with transvaginal ultrasound, as the 2026 ACOG update recommends instead of relying on a thin endometrium. Qualitative results (pathology, immunohistochemistry, methylation, POLE, hepatitis and HIV serology, imaging, mammogram) appear only in procedure and note text. Height (165 cm) and weights are synthetic; BMI 26 to 27 is not coded as a problem.
- **Preventive visit.** A periodic adult preventive visit at 60 (CPT 99396 with 99497 in plain text), six weeks after the end of combination treatment and on the day of the second maintenance dose. Judgment calls: cervical screening not indicated after total hysterectomy for cancer, with no vaginal cytology; average-risk colorectal screening because the mismatch repair loss is acquired; PCV20 under the current recommendation for all adults from 50; recombinant zoster and Tdap given; bone density deferred to 65 with no added risk factor; influenza and COVID-19 vaccines in the autumn. Advance care planning records only her general preferences and an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (two weeks with the diagnosis and consultation, three weeks after surgery with cycle 1, cycle 4, and the end of combination treatment with the first maintenance dose) are documented as focused visits on the NCCN uterine neoplasms guideline, the CMID endometrial cancer monograph, FIGO 2023, the RUBY trial and dostarlimab label, the ASCO immune-related adverse event, antiemetic, neuropathy and hepatitis B guidance, and the 2026 SGO surveillance statement. One deviation is recorded instead of an invented result: the morning cortisol that the CMID protocol calls for at baseline and before each checkpoint inhibitor cycle was deferred at cycle 1 (she arrived after the morning window) and then missed before cycles 2 and 3 because the request did not reach the infusion center’s standing orders; no harm resulted (normal at cycle 4 and at the end of treatment, no symptoms), and the standing orders were corrected. Synthetic findings introduced: grade 1 paclitaxel neuropathy at cycle 4, a TSH just above range at cycle 4, and grade 2 immune-related hypothyroidism at the end of combination treatment, treated with levothyroxine while dostarlimab continued.
- **Consultation.** The gynecologic oncology referral, written at intake when only the bleeding was known, and the consultation by Miriam Delacroix, MD (a fictional consultant), on the day of the two-week visit, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: minimally invasive hysterectomy with sentinel node mapping and removal of the enlarged pelvic and para-aortic nodes; MLH1 methylation, POLE and FIGO 2023 staging with the molecular class; dostarlimab with carboplatin and paclitaxel if nodal disease was confirmed, which it was; genetic counseling, with germline testing only if methylation did not explain the MLH1 loss; the immune-related monitoring that found her hypothyroidism; and the survivorship schedule.
